Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 24;9(31):22038-22046.
doi: 10.18632/oncotarget.25157.

Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule

Adeline Pêtre  1 , Cécile Dalban  1 , Andy Karabajakian  1 , Eve-Marie Neidhardt  1 , Pierre Eric Roux  1 , Marc Poupart  1 , Sophie Deneuve  1 , Philippe Zrounba  1 , Jérome Fayette  1
Affiliations

Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule

Adeline Pêtre et al. Oncotarget. .

Abstract

The standard first-line treatment in recurrent/metastatic head and neck squamous cell carcinoma combines Cisplatin, 5 Fluorouracil and Cetuximab, but many patients aren't eligible. We retrospectively evaluated the efficacy and the tolerability of Carboplatin and Paclitaxel in this indication, mostly in patients unfit to Cisplatin. Paclitaxel (80mg/m2) was administered at day 1, 8 and 15 and Carboplatin area under the curve 5 at day 1, repeated every 28 days, for 6 cycles. Carboplatin could be administered at area under the curve 2 at day 1, 8 and 15. 117 patients received this association at our institution, 94 of those were ineligible to cisplatin due to severe comorbidities, age >70years or Performance status >1. The overall response rate was 40%. The median progression free survival for patients ineligible to Cisplatin was 4.4 months [95% CI; 3.4; 5.0] and the median overall survival was 8 months [95% CI; 5.4-10.7]. The most frequent toxicities were hematologic, with 94 grade ≥ 3, mostly in patients who received monthly Carboplatin. Our study shows Carboplatin and Paclitaxel in first-line in recurrent/metastatic head and neck squamous cell carcinoma appear efficient for patients ineligible to Cisplatin and safe when both drugs are weekly administered.

Keywords: first-line; head and neck cancer; metastasis; recurrence; unfit.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST Jérome Fayette has been paid honoraria by BMS.

Figures

Figure 1
Figure 1. Delivery of carboplatin and paclitaxel
Figure 2
Figure 2. OS of population
OS of all population (A), in eligible and no eligible group (B), in PS 0/1, 2 and 3 of no eligible group (C).
Figure 3
Figure 3. PFS of population
PFS of all population (A), in eligible and no eligible group (B), in PS 0/1, 2 and 3 of no eligible group (C).
See this image and copyright information in PMC

References

    1. Fact Sheets by Population Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
    1. Shetty AV, Wong DJ. Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck. Otolaryngol Clin North Am. 2017;50:775–82. https://doi.org/10.1016/j.otc.2017.03.013. - DOI - PubMed
    1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695–709. https://doi.org/10.1016/S0140-6736(08)60728-X. - DOI - PMC - PubMed
    1. Fayette J, Montella A, Chabaud S, Bachelot T, Pommier P, Girodet D, Racadot S, Montbarbon X, Favier B, Zrounba P. Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution. Anticancer Drugs. 2010;21:553–58. https://doi.org/10.1097/CAD.0b013e3283388e60. - DOI - PubMed
    1. Magnes T, Melchardt T, Weiss L, Mittermair C, Neureiter D, Klieser E, Gampenrieder S, Moser G, Gaggl A, Greil R, Egle A. Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. PLoS One. 2017;12:e0180995. https://doi.org/10.1371/journal.pone.0180995. - DOI - PMC - PubMed